AZ6102TNKS1/2 inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
AZ6102 Dilution Calculator
calculate
AZ6102 Molarity Calculator
calculate
Cas No. | 1645286-75-4 | SDF | Download SDF |
Chemical Name | 2-(4-(6-((3S,5R)-3,5-dimethylpiperazin-1-yl)-4-methylpyridin-3-yl)phenyl)-7-methyl-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one | ||
Canonical SMILES | O=C1NC(C2=CC=C(C3=CN=C(N4C[C@H](C)N[C@H](C)C4)C=C3C)C=C2)=NC5=C1C=CN5C | ||
Formula | C25H28N6O | M.Wt | 428.53 |
Solubility | Soluble in DMSO | Storage | Store at -20°C |
Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
IC50: 1 and 3 nM for TNKS2 and TNKS1, respectively
AZ6102 is a TNKS1/2 inhibitor.
Inhibition of the poly(ADP-ribose) polymerase (PARP) catalytic domain of the tankyrases (TNKS1 and TNKS2) is reported to inhibit the Wnt pathway by increasing stabilization of Axin. The canonical Wnt pathway plays a critical role in adult tissue homeostasis, embryonic development, as well as cancer.
In vitro: AZ6102 was identified as a potent TNKS1/2 inhibitor with 100-fold selectivity against other PARP family enzymes including PARPs 1, 2, and 6. In addition, AZ6102 showed a 5 nM IC50 against Wnt pathway in DLD-1 cells [1].
In vivo: In animal study, AZ6102 was intravenously dosed to nude mice at 25 mg/kg, and the results showed that AZ6102 had a clearance of 24 mL/min·kg and a half-life of 4 h. The bioavailability of AZ6102 in mouse and rat was only moderate at 12% and 18%, respectively. In addition, AZ6102 was used as an intravenous probe compound to evaluate the in vivo effects of TNKS1/2 inhibition on normal tissue and tumor xenografts, however, the results of such experiments have not be released so far [1].
Clinical trial: Up to now, AZ6102 is still in the preclinical development stage.
Reference:[1] J. W. Johannes, L. Almeida, B. Barlaam,et al.Pyrimidinone nicotinamide mimetics as selective tankyrase and Wnt pathways inhibitors suitable for in vivopharmacology. ACS Med. Chem. Lett. 6, 254-259 (2015).